2014
DOI: 10.1016/b978-0-444-63380-4.00004-4
|View full text |Cite
|
Sign up to set email alerts
|

Recent Progress in the Discovery and Development of N-Type Calcium Channel Modulators for the Treatment of Pain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
21
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(21 citation statements)
references
References 127 publications
(156 reference statements)
0
21
0
Order By: Relevance
“…Previous study has linked CACNA1B (Ca v 2.2) to neuropathic pain [43, 44] and CACNA1B (Ca v 2.2) mutation (R1389H) has been linked to myoclonus-dystonia syndrome, a rare movement disorder [45]. Very little is known about its role in carcinogenesis, except overexpression of CACNA1B (Ca v 2.2) was detected in both prostate and breast cancer [15].…”
Section: Discussionmentioning
confidence: 99%
“…Previous study has linked CACNA1B (Ca v 2.2) to neuropathic pain [43, 44] and CACNA1B (Ca v 2.2) mutation (R1389H) has been linked to myoclonus-dystonia syndrome, a rare movement disorder [45]. Very little is known about its role in carcinogenesis, except overexpression of CACNA1B (Ca v 2.2) was detected in both prostate and breast cancer [15].…”
Section: Discussionmentioning
confidence: 99%
“…The use of ziconotide, however, is encumbered by difficult dosing regimens, a very narrow therapeutic window, and numerous side effects including dizziness, nausea, nystagmus, memory impairment, and hallucinations [68; 75; 76; 82]. Nevertheless, the clinical efficacy of ziconotide, supports the development of novel CaV2.2-targeted compounds with superior properties [49; 95]. …”
Section: Introductionmentioning
confidence: 99%
“…Min Li (Johns Hopkins University) (49) discussed his work in developing and understanding the mechanisms of allosteric modulation of KCNQ family potassium channels by small molecules. Margaret Lee (Zalicus, Cambridge, MA, USA) (50) described development of novel, small molecules that state‐dependently target calcium channels to treat pain, and the role of metabotropic glutamate receptor 1 (mGluR1)/GluR δ2 (GluRd2) complexes in cerebellar signaling was presented by David Bredt (Johnson & Johnson, San Diego, CA, USA) (51). Session Chair Colleen Clancy (University of California, Davis, CA, USA) (52) rounded off the morning with a demonstration of the power of computational modeling in predicting and understanding drug‐channel interactions and their role in treating cardiac arrhythmias.…”
Section: Overview Of the Scientific Sessionsmentioning
confidence: 99%